Empowered Funds LLC Buys New Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Empowered Funds LLC purchased a new position in Sage Therapeutics, Inc. (NASDAQ:SAGE) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,680 shares of the biopharmaceutical company’s stock, valued at approximately $91,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Sage Therapeutics by 66.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 4,672 shares during the last quarter. Creative Planning purchased a new position in shares of Sage Therapeutics during the third quarter valued at approximately $88,000. Quest Partners LLC boosted its position in shares of Sage Therapeutics by 56.3% during the third quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 6,618 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Sage Therapeutics during the third quarter valued at approximately $146,000. Finally, SG Americas Securities LLC boosted its position in shares of Sage Therapeutics by 57.7% during the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 8,228 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Stock Performance

NASDAQ:SAGE opened at $7.31 on Friday. Sage Therapeutics, Inc. has a one year low of $4.62 and a one year high of $23.22. The firm has a market cap of $449.42 million, a price-to-earnings ratio of -1.11 and a beta of 0.94. The firm’s fifty day moving average is $6.55 and its two-hundred day moving average is $6.80.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. As a group, equities research analysts predict that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on SAGE shares. Stifel Nicolaus dropped their price target on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a report on Monday, December 16th. Canaccord Genuity Group dropped their price target on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, February 12th. Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target on the stock in a report on Thursday, November 21st. Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Scotiabank dropped their price target on Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a report on Wednesday, February 12th. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Sage Therapeutics has a consensus rating of “Hold” and a consensus target price of $9.65.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.